Bayer Yakuhin will shift its management resources to innovative products such as the anticoagulant drug Xarelto (rivaroxaban), the anticancer agent Stivarga (regorafenib), and the wet age-related macular degeneration (AMD) treatment Eylea (aflibercept), President Carsten Brunn said in a recent interview…
To read the full story
BUSINESS
- Teijin, ASKA Hook Up on Gynecology Drug Discovery
February 18, 2026
- Fycompa Generics Approved despite Extended Patent, Hydrate Switch in Play?
February 17, 2026
- Espha Snags Bilanoa AG in Final Pre-Rule Approval Window
February 17, 2026
- Rakuten to Launch Japan PI of RM-0256 Photoimmunotherapy in April-June
February 17, 2026
- Kidswell, Treehill to Form US Firm for Cell Therapy Development
February 17, 2026
The Japanese healthcare sector is experiencing rapid growth, demanding a highly skilled and diverse workforce. However, finding and attracting the best talent in this competitive market presents significant challenges.Enter AI. With the rise of AI-powered tools, healthcare organizations can revolutionize…





